Status: Recruiting
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Participants needed: 75
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: YOUNGIL KOHUpdated: Dec 3, 2025Locations: 7
Eligibility criteria
Subject is ≥ 19 years of age at the time of signing the informed consent form (I... [+7]
1 Subject who has had prior treatment with mezigdomide. 2 Patients with gastroin...